Mark Landers

2.0k citations

42 papers · 1.6k indexed · 1 hit paper · h-index 15

Impact in

Cancer Research top 5%
- Cancer Genomics and Diagnostics
Physiology top 5%

Papers in ⓘ

Oncology 25
- Cancer Cells and Metastasis 16
- Cancer Immunotherapy and Biomarkers 5
- PARP inhibition in cancer therapy 4
Cancer Research 23
- Cancer Genomics and Diagnostics 22

Co-authors: Barbara E. Ehrlich (1 shared paper)Elena Ondriašová (1 shared paper)Karol Ondriaš (1 shared paper)Evgeny Kobrinsky (1 shared paper)Maria C. Moschella (1 shared paper)Thottala Jayaraman (1 shared paper)Andrew Scott (1 shared paper)Andrew R. Marks (1 shared paper)
Journals: Journal of Clinical Oncology (16 papers)Cancer Research (8 papers)Nucleic Acids Research (2 papers)PLoS ONE (2 papers)Clinical Cancer Research (1 paper)
Partner nations: United States United Kingdom France

In The Last Decade

Mark Landers

40 papers receiving 1.6k citations

Hit Papers

align trajectories log scale

Stabilization of calcium release channel (ryanodine receptor) function by FK506-binding protein 1994 · 679 citations

Peers

Countries citing papers authored by Mark Landers

Since Specialization

Citations

This map shows the geographic impact of Mark Landers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Landers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Landers more than expected).

Fields of papers citing papers by Mark Landers

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Landers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Landers. The network helps show where Mark Landers may publish in the future.

Co-authors

The 25 scholars most cited alongside Mark Landers, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark Landers Line = papers co-authored together Mark Landers links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 42 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Stabilization of calcium release channel (ryanodine receptor) function by FK506-binding protein Cell ·Anne-Marie B. Brillantes, Karol Ondriaš, Andrew Scott, Evgeny Kobrinsky, Elena Ondriašová, Maria C. Moschella, Thottala Jayaraman, Mark Landers, Barbara E. Ehrlich, Andrew R. Marks Hit paper breakdown →	1994	679
2	Regulation of the large ( 1000 kb) imprinted murine Ube3a antisense transcript by alternative exons upstream of Snurf/Snrpn Nucleic Acids Research ·Mark Landers	2004	128
3	The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate Cancer Clinical Cancer Research ·Himisha Beltran, Adam Jendrisak, Mark Landers, Juan Miguel Mosquera, Myriam Kossaï, Jessica Louw, Rachel Krupa, Ryon P. Graf, Nicole A. Schreiber, David M. Nanus, Scott T. Tagawa, Dena Marrinucci, Ryan Dittamore, Howard I. Scher	2015	108
4	Analytical Validation and Capabilities of the Epic CTC Platform: Enrichment-Free Circulating Tumour Cell Detection and Characterization SHILAP Revista de lepidopterología ·Shannon L. Werner, Ryon P. Graf, Mark Landers, David T. Valenta, Matthew Schroeder, Stephanie Greene, Natalee Bales, Ryan Dittamore, Dena Marrinucci	2015	100
5	Phenotypic Heterogeneity of Circulating Tumor Cells Informs Clinical Decisions between AR Signaling Inhibitors and Taxanes in Metastatic Prostate Cancer Cancer Research ·Howard I. Scher, Ryon P. Graf, Nicole A. Schreiber, Brigit McLaughlin, Adam Jendrisak, Yipeng Wang, Jerry Lee, Stephanie Greene, Rachel Krupa, David Lu, Pascal Bamford, Jessica E. Louw, Lyndsey Dugan, Hebert Alberto Vargas, Martin Fleisher, Mark Landers, Glenn Heller, Ryan Dittamore	2017	94
6	HYDICE: an airborne system for hyperspectral imaging Proceedings of SPIE, the International Society for Optical Engineering/Proceedings of SPIE ·L. J. Rickard, Robert W. Basedow, Edward F. Zalewski, Peter R. Silverglate, Mark Landers	1993	86
7	High Resolution Detection and Analysis of CpG Dinucleotides Methylation Using MBD-Seq Technology PLoS ONE ·Xun Lan, Christopher M. Adams, Mark Landers, Miroslav Dudas, Daniel Krissinger, George E. Marnellos, Russell Bonneville, Maoxiong Xu, Junbai Wang, Tim H-M. Huang, Gavin Meredith, Victor X. Jin	2011	65
8	Cellular Expression of PD-L1 in the Peripheral Blood of Lung Cancer Patients is Associated with Worse Survival Cancer Epidemiology Biomarkers & Prevention ·Daniel J. Boffa, Ryon P. Graf, Michelle C. Salazar, Jessica R. Hoag, David Lu, Rachel Krupa, Jessica Louw, Lyndsey Dugan, Yipeng Wang, Mark Landers, Mahipal Suraneni, Stephanie Greene, Marisa Magaña, Samir Makani, Lyudmila Bazhenova, Ryan Dittamore, Jorge J. Nieva	2017	61
9	Phenotypic diversity of circulating tumour cells in patients with metastatic castration‐resistant prostate cancer British Journal of Urology ·Andrew S. McDaniel, Roberta Ferraldeschi, Rachel Krupa, Mark Landers, Ryon P. Graf, Jessica Louw, Adam Jendrisak, Natalee Bales, Dena Marrinucci, Zafeiris Zafeiriou, Penelope Flohr, Spyridon Sideris, Mateus Crespo, Ines Figueiredo, Joaquı́n Mateo, Johann S. de Bono, Ryan Dittamore, Scott A. Tomlins, Gerhardt Attard	2016	51
10	Maternal disruption of Ube3a leads to increased expression of Ube3a-ATS in trans Nucleic Acids Research ·Mark Landers	2005	47
11	Chromosomal Instability Estimation Based on Next Generation Sequencing and Single Cell Genome Wide Copy Number Variation Analysis PLoS ONE ·Stephanie Greene, Angel E. Dago, Laura Leitz, Yipeng Wang, Jerry Lee, Shannon L. Werner, Steven Gendreau, Premal H. Patel, Shidong Jia, Liangxuan Zhang, Eric Tucker, Michael Malchiodi, Ryon P. Graf, Ryan Dittamore, Dena Marrinucci, Mark Landers	2016	37
12	Morphology-Predicted Large-Scale Transition Number in Circulating Tumor Cells Identifies a Chromosomal Instability Biomarker Associated with Poor Outcome in Castration-Resistant Prostate Cancer Cancer Research ·Joseph D. Schonhoft, Jimmy L. Zhao, Adam Jendrisak, Emily Carbone, Ethan Barnett, Melanie Hullings, Audrey Gill, Ramsay Sutton, Jerry Lee, Angel E. Dago, Mark Landers, Samuel F. Bakhoum, (unknown), Mithat Gönen, Ryan Dittamore, Howard I. Scher	2020	32
13	Genomic Analysis of Circulating Tumor Cells at the Single-Cell Level Journal of Molecular Diagnostics ·Shan Lu, Chia-Jung Chang, Yinghui Guan, Edith Szafer‐Glusman, Elizabeth A. Punnoose, An D, Becky Suttmann, Ross Gagnon, Ángel Rodríguez, Mark Landers, Jill M. Spoerke, Mark R. Lackner, Wenzhong Xiao, Yulei Wang	2020	24
14	An alignment algorithm for bisulfite sequencing using the Applied Biosystems SOLiD System Bioinformatics ·Brian Ondov, Charles Cochran, Mark Landers, Gavin Meredith, Miroslav Dudas, Nicholas H. Bergman	2010	17
15	Correlation of FCGRT genomic structure with serum immunoglobulin, albumin and farletuzumab pharmacokinetics in patients with first relapsed ovarian cancer Genomics ·Daniel J. O’Shannessy, Katie Bendas, Charles Schweizer, Wenquan Wang, Earl F. Albone, Elizabeth B. Somers, Susan C. Weil, Rhonda Meredith, Jason Wustner, Luigi Grasso, Mark Landers, Nicholas C. Nicolaides	2017	15
16	CTC enumeration and characterization as a pharmacodynamic marker in the phase I clinical study of APX3330, an APE1/Ref-1 inhibitor, in patients with advanced solid tumors. Journal of Clinical Oncology ·Lincy Chu, Amanda Anderson, Mark Landers, (unknown), Mark R. Kelley, Richard A. Messmann	2019	9
17	Analytical Validation and Capabilities of the Epic CTC Platform: Enrichment-Free Circulating Tumour Cell Detection and Characterization Shannon L. Werner, Ryon P. Graf, Mark Landers, David T. Valenta, Matthew Schroeder, Stephanie Greene, Natalee Bales, Ryan Dittamore, Dena Marrinucci	2015	8
18	Detection and Characterization of Circulating Tumour Cells from Frozen Peripheral Blood Mononuclear Cells PubMed ·David Lu, Ryon P. Graf, Melissa Harvey, Ravi A. Madan, Christopher R. Heery, Jennifer L. Marté, Sharon Beasley, Kwong Y. Tsang, Rachel Krupa, Jessica Louw, Justin Wahl, Natalee Bales, Mark Landers, Dena Marrinucci, Jeffrey Schlom, James L. Gulley, Ryan Dittamore	2015	8
19	Pamiparib, an investigational PARP inhibitor, in patients with metastatic castration-resistant prostate cancer (mCRPC) and a circulating tumor cell (CTC) homologous recombination deficiency (HRD) phenotype or BRCA defects: A trial in progress. Journal of Clinical Oncology ·Simon Chowdhury, Joaquı́n Mateo, Mitchell E. Gross, Andrew J. Armstrong, Marcia Cruz‐Correa, Josep M. Piulats, Jean‐Yves Blay, Miao Li, Delcia Rivas, Luis Quintero, Henry Castro, Andong Nkobena, Mitch Raponi, Robert J. Pelham, Mark Landers, Bruce Montgomery	2019	5
20	AR-V7 and CTC heterogeneity biomarkers additively to predict patient (pt) outcomes with taxanes relative to approved AR targeted therapy. Journal of Clinical Oncology ·Howard I. Scher, Ryon P. Graf, Nicole A. Schreiber, Brigit McLaughlin, David Lu, Jessica Louw, Adam Jendrisak, Stephanie Greene, Ángel Rodríguez, Lyndsey Dugan, Martin Fleisher, Jerry Lee, Yipeng Wang, Mark Landers, Ryan Dittamore	2016	4

About Mark Landers

Mark Landers is a scholar working on Oncology, Cancer Research, Pulmonary and Respiratory Medicine, Molecular Biology and Radiology, Nuclear Medicine and Imaging, having authored 42 papers that have together received 1.6k indexed citations. Recurring topics across this work include Cancer Genomics and Diagnostics (22 papers), Cancer Cells and Metastasis (16 papers), Prostate Cancer Treatment and Research (14 papers), Radiopharmaceutical Chemistry and Applications (5 papers), Cancer Immunotherapy and Biomarkers (5 papers), Epigenetics and DNA Methylation (4 papers), PARP inhibition in cancer therapy (4 papers) and Molecular Biology Techniques and Applications (3 papers). The work is most often cited by research in Cancer Research (400 citations), Physiology (97 citations), Oncology (447 citations), Molecular Biology (1.0k citations) and Sensory Systems (61 citations). Mark Landers has collaborated with scholars based in United States, United Kingdom and France. Frequent co-authors include Barbara E. Ehrlich, Elena Ondriašová, Karol Ondriaš, Evgeny Kobrinsky, Maria C. Moschella, Thottala Jayaraman, Andrew Scott, Andrew R. Marks, Ryan Dittamore and Ryon P. Graf. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Nucleic Acids Research, PLoS ONE and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact